Replies to post #95746 on $heff's $tation of $tocks & $olid DD

[ash111]

$XTNT DD sayin exactly the opposite, can't find a reason for this,days will tell:
GOLDMAN CAPITAL MANAGEMENT INC is the Largest institutional here $124,212,000 Portfolio Q32016
Goldman Capital Management Inc buys $600,386 stake in Xtant Medical Holdings Inc (XTNT) http://www.thefoundersdaily.com/goldman-capital-management-inc-buys-600386-stake-in-xtant-medical-holdings-inc-xtnt/695041/

Cap under $10m, Gross Profit almost doubled (9 months) 44,782,498 vs 24,205,310, 3 months up almost 50%.solid balance sheet too:

Total current assets(45,767,950) /Total current liabilities(28,469,386) ratio= ~1.7 (Solid)
Total assets(142,448,965)/Total liabilities(including long term debt,147,547,884) ratio = ~1

"The company has a consensus rating of Buy and a consensus price target of $4.45".

http://www.financial-market-news.com/xtant-medical-holdings-inc-xtnt-now-covered-by-analysts-at-maxim-group/1223882/

Beside a Record revenue the Company recently did some more major steps forward :

1. Uplisted to NYSE MKT (October 19, 2015)

2. its wholly owned subsidiary, Bacterin International, Inc., has received notification that the United States Patent and Trademark Office has issued US Patent No. 9,114,191 entitled "Process for Demineralization of Bone Matrix with Preservation of Natural Growth Factors." (Sep 22, 2015)

3. “Xtant Medical Received FDA Clearance for the Xsert™ Lumbar Expandable Interbody
System,” (Nov 23, 2016). Xtant Medical estimates the U.S market for lumbar interbody devices at $1.3M and growing. The worldwide market for Demineralized Bone Matrix
(DBM) is estimated at $485M. 
Xsert will be available in an initial product release in mid 2017.
btw. also Received FDA Clearance +CE Mark of the Aranax(TM) Cervical Plate.

4. Five investment analysts have rated the stock with a buy rating, The company has a consensus rating of Buy and a consensus price target of $4.45. including a new Covered by Analysts at Maxim Group (on last friday).